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Medicines have evolved over time and so has the realisation of the 
importance of quality control and regulatory processes. Catastrophes 
such as the thalidomide disaster in the late 1950s highlighted the 
importance of regulating medicines on the grounds of safety, quality 
and efficacy, which has since been widely accepted and implemented.
[1] The most important objective of medicine regulation is to ensure 
the safety of consumers. As medicine as such is not safe, the choice 
between the risk and benefit associated with its use needs to be made 
on the consumer’s behalf by means of regulations. The regulatory 
practices include all the steps from the development and manufac-
ture of the active ingredients, to packaging and distribution, until the 
medicines reach the consumer. [2] In South Africa (SA), as in other 
countries, the public has the right to expect that only safe and effec-
tive medicines of good quality are allowed on the market, aligned 
with section 12 of the Constitution of SA.[3]
The establishment of the Medicines Control Council (MCC), man-
dated to regulate medicines in SA, was provided for by the Medicines 
and Related Substances Act 101 of 1965 (Medicines Act).[2] The 
Medicines Act provides in section 14(2)(a) that the MCC may from 
time to time by resolution approved by the minister of health deter-
mine that a medicine or class or category of medicines or part of any 
class or category of medicines mentioned in the resolution shall be 
subject to registration in terms of the Medicines Act. Medicines were 
called up for registration according to this section and if a medicine 
became subject to registration and was not subsequently registered, 
its sale was prohibited according to section 14(1).[4]
Regulation of complementary 
medicines 
Complementary medicines were previously perceived to be 
unregulated, although the Medicines Act does not distinguish 
between allopathic and complementary medicine. In 2002, the MCC 
published a notice, ‘Call up notice for medicines frequently referred 
to as complementary medicines in terms of the Medicines and 
Related Substances Act, 1965 (Act No. 101 of 1965)’.[5] The Notice 
also indicated that the data compiled from this call-up will enable 
Council to audit all products currently available on the market. 
Council will review the claims of safety, quality and efficacy for all 
identified products and will determine whether any such claims 
constitute a public health hazard and act accordingly. The MCC 
requested manufacturers to submit a document providing limited 
information on the medicines. The shortened application form 
included administrative information, a copy of the label and package 
insert, a breakdown of the unit formulation, and a list of other 
countries in which the product is sold. These application forms did 
not contain sufficient information for evaluation of safety, quality 
and efficacy and were intended as an audit process only. MBR20.8 
documents were issued by the MCC as confirmation of receipt of the 
abbreviated application and did not indicate product registration.[6] 
Even though the audit period, as indicated in the Notice, expired on 
22 August 2002, submissions from manufacturers continued, to some 
extent to obtain a National Pharmaceutical Product/Pricing Index 
(NAPPI) code.[7]
In the case between the Treatment Action Campaign v Rath and 
Others (12156/05 (2008) ZAWCHC 34), Rath was found guilty of 
selling and distributing medicines that were not registered and 
that contained scheduled substances.[8] He was also found guilty 
of making false and unauthorised statements about the efficacy of 
medicines. In the High Court judgment Judge Zonde ruled against 
Rath and others on the grounds of the main purpose of the 2002 
call-up by the MCC. He further mentioned that the MCC has failed 
to determine the correctness of the claims made for products that 
have been submitted. Furthermore, the MCC did not carry out an 
independent assessment of quality of these products; therefore, the 
products must be considered to be potentially unsafe. Any claims 
made about these medicines would therefore be considered to be 
misleading. The regulation of complementary medicines did not 
entail an amendment to the Act, as sections 14 and 15 imply that they 
have already been ‘called up for registration’. This cannot be repealed 
by the 2002 call-up.
However, Government Notice R870, published in the Government 
Gazette 37032 of 15 November 2013, incorporated new General 
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Regulations to the Medicines Act, which finally called up comple-
mentary medicines.[9] This amendment provides that all comple-
mentary medicines will be subject to the same legislative control as 
allopathic medicines. Complementary medicines will be evaluated 
for safety, efficacy and quality and claims made will have to be sub-
stantiated. Furthermore, manufacturers, distributors, importers and 
exporters of complementary medicines will have to be licenced. 
The amended Regulations defined complementary medicines 
as any substance or mixture of substance that (i) originates from 
plants, minerals or animals; (ii) is used or intended to be used for, or 
manufactured or sold for use in assisting the innate healing power 
of a human being or animal to mitigate, modify, alleviate or prevent 
illness or the symptoms thereof or abnormal physical or mental state; 
and (iii) is used in accordance with the practice of the professions 
regulated under the Allied Health Professions Act, 1982 (Act No. 63 
of 1982).[9] 
The disciplines or practices mentioned in part (iii) of the 
definition include homeopathy, western herbal medicine, traditional 
Chinese medicine, Ayurveda, Unani medicine (Unani-Tibb) and 
aromatherapy.[10] Each discipline has different requirements governed 
by its own references and pharmacopoeia subject to the current 
science and knowledge of the particular discipline. 
The definition proved problematic, as it does not provide for 
the origin, claims and/or uses of all perceived complementary 
medicines such as certain vitamin products and probiotics, which 
are not discipline specific and have not been used in accordance with 
the practice of the professions regulated under the Allied Health 
Professions Act as indicated in the abovementioned definition.[9,10]
An amended definition of complementary medicines has been 
published for comment, which defines these medicines as any 
substance or mixture of substances that (i) originates from plants, 
fungi, algae, seaweeds, lichens, minerals, animals or other substance 
as determined by Council; and (ii) is used or purports to be 
suitable for use or is manufactured or sold for use in maintaining, 
complementing, or assisting the innate healing power or physical 
or mental state; or to diagnose, treat, mitigate, modify, alleviate 
or prevent disease or illness or the symptoms or signs thereof or 
abnormal physical or mental state of a human being or animal; 
and (iii) is used as a health supplement; or in accordance with 
those disciplines as determined by Council; or (iv) is declared by 
the Minister, on recommendation by the Council, by notice in the 
Government Gazette to be a complementary medicine.[11] 
The proposed amendments to the complementary medicine 
definition provide additional origins, widen the claims and added a 
subcategory, i.e. health supplements, to the initial definition. They 
also provide for a medicine that does not meet the requirements 
to be declared a complementary medicine by the Minister on 
recommendation by the MCC. Combination products, such as 
products comprised of more than one discipline-specific substance 
or discipline-specific substance(s) and health supplements, are also 
classified as a category of complementary medicines.
If a medicine does not meet any of the abovementioned require-
ments to be defined as a complementary medicine, selling will have to 
be discontinued and application will have to be made for registration 
as an allopathic medicine. 
The claims of complementary medicines create pharmacological 
classifications, and medicines have to be submitted on designated 
dates, depending on their classification, e.g. antiviral complementary 
medicines had to be submitted by May 2014. The initial submission 
process will be completed by November 2019. The requirement for 
only submitting on a designated date in future was that the medicines 
must have been available for sale in SA on the date of Notice R870. In 
the meantime, the status quo is maintained and the medicine may be 
sold unless it contains banned or scheduled substances.[12] 
Interestingly, the Medicines and Related Substances Amendment 
Act 2015[13] provides for the establishment of the SA Health Products 
Regulatory Authority, which will replace the current MCC, but this 
Act will only become operational after the commencement of the 
Medicines and Related Substances Amendment Act 2008.[14] It will 
not have an effect on the call-up or definitions of complementary 
medicines.
Quality, safety and efficacy of 
complementary medicines
The labels of all complementary medicines must comply with the 
provisions of section 8 of the General Regulations to Medicines and 
Related Substances Act, 1965. According to these provisions, the labels 
must be written in English and at least one other official language 
and must indicate the category, pharmacological classification and 
discipline of medicine. Furthermore, the words ‘This medicine has 
not been evaluated by the Medicines Control Council. This medicine 
is not intended to diagnose, treat, cure or prevent any disease’ must be 
added to the label.[15] Any additional information to the regulations 
has to be authorised by the MCC.
The quality of complementary medicines is measured in terms 
of factors such as Good Manufacturing Practice (GMP), Good 
Laboratory Practice and Good Agricultural and Collection Practices 
specifi cations, identification of impurities, analytical validations 
and stability (International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use (ICH) guidelines), 
ensuring attributes such as identity, strength and purity of a medicine 
that have to be met consistently.[16,17] 
When evaluating the efficacy of complementary medicines, 
established traditional use, preclinical data and evidence from clinical 
trials in animals and humans are used. Literature, such as acceptable 
monographs and pharmacopoeial references, also needs to be taken 
into account to the extent depending on the risk level of the claim 
made. The data must support efficacy aligned with the proposed 
indications and claims on the label and package insert.
Safety may be established by detailed reference to the published 
literature and/or the submission of original study data. If a comple-
mentary medicine has been traditionally used without demonstra-
ting harm, a review of the relevant literature should be provided. 
Reference should also be made to official monographs supporting 
safety and toxicological studies, if available. Safety is the ability of the 
medicine not to cause serious side-effects when assessed against its 
risk-benefit profile. 
Conclusion
The General Regulations of 2013[9] ended an era of unregulated 
commercialisation of complementary medicine. Unfortunately, the 
requirements in terms of dossier content left many role-players 
at odds. Without the much needed pharmacological and scien-
tific knowledge, the compilation of dossiers becomes an insurmount-
able task. Furthermore, the cost of merely applying, especially for 
those companies currently selling many products, is daunting.[18] 
Overcoming these hurdles is extremely expensive and time-consum-
ing. Conflict between reputable trademarks and allowed proprietary 
names and acceptable levels of proof of efficacy, among other issues, 
may also cause disputes between the industry and the MCC. The 
majority of complementary medicines that were on the market before 
the General Regulations came into effect, are now under threat and 
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the nature of the industry will change once the new laws are fully 
implemented. 
However, the MCC has a mandate to ensure that the registration 
of a medicine is in the interest of the public. It will surely not be in 
the public interest to register a complementary or any other medicine 
that is manufactured in a facility not adhering to GMP, according to 
which efficacy and safety are not supported by trustworthy data, and 
the shelf-life is not known. As stated above, medicine as such is not 
safe and the choice between the risk and benefit associated with the 
use of medicine needs to be made on the consumer’s behalf, by means 
of regulations.
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